» Articles » PMID: 25153721

PTK6/BRK is Expressed in the Normal Mammary Gland and Activated at the Plasma Membrane in Breast Tumors

Overview
Journal Oncotarget
Specialty Oncology
Date 2014 Aug 26
PMID 25153721
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Protein Tyrosine kinase 6 (PTK6/BRK) is overexpressed in the majority of human breast tumors and breast tumor cell lines. It is also expressed in normal epithelial linings of the gastrointestinal tract, skin, and prostate. To date, expression of PTK6 has not been extensively examined in the normal human mammary gland. We detected PTK6 mRNA and protein expression in the immortalized normal MCF-10A human mammary gland epithelial cell line, and examined PTK6 expression and activation in a normal human breast tissue microarray, as well as in human breast tumors. Phosphorylation of tyrosine residue 342 in the PTK6 activation loop corresponds with its activation. Similar to findings in the prostate, we detect nuclear and cytoplasmic PTK6 in normal mammary gland epithelial cells, but no phosphorylation of tyrosine residue 342. However, in human breast tumors, striking PTK6 expression and phosphorylation of tyrosine 342 is observed at the plasma membrane. PTK6 is expressed in the normal human mammary gland, but does not appear to be active and may have kinase-independent functions that are distinct from its cancer promoting activities at the membrane. Understanding consequences of PTK6 activation at the plasma membrane may have implications for developing novel targeted therapies against this kinase.

Citing Articles

A PROTAC degrader suppresses oncogenic functions of PTK6, inducing apoptosis of breast cancer cells.

Martinez C, Xiong Y, Bartkowski A, Harada I, Ren X, Byerly J Cell Chem Biol. 2024; 32(2):255-266.e8.

PMID: 39541980 PMC: 11845306. DOI: 10.1016/j.chembiol.2024.10.008.


PTK6: An emerging biomarker for prognosis and immunotherapeutic response in clear cell renal carcinoma (KIRC).

Lin L, Gong S, Deng C, Zhang G, Wu J Heliyon. 2024; 10(7):e29001.

PMID: 38596018 PMC: 11002233. DOI: 10.1016/j.heliyon.2024.e29001.


MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases.

Ito K, Harada I, Martinez C, Sato K, Lee E, Port E Cancer Res Commun. 2024; 4(3):946-957.

PMID: 38457262 PMC: 10977041. DOI: 10.1158/2767-9764.CRC-23-0090.


In Silico Screening of Multi-Domain Targeted Inhibitors for PTK6: A Strategy Integrating Drug Repurposing and Consensus Docking.

Zhou Y, Wong M Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256893 PMC: 10818313. DOI: 10.3390/ph17010060.


Therapeutic Potential of Protein Tyrosine Kinase 6 in Colorectal Cancer.

Jerin S, Harvey A, Lewis A Cancers (Basel). 2023; 15(14).

PMID: 37509364 PMC: 10377740. DOI: 10.3390/cancers15143703.


References
1.
Harvey A, Crompton M . Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene. 2003; 22(32):5006-10. DOI: 10.1038/sj.onc.1206577. View

2.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

3.
Li X, Lu Y, Liang K, Hsu J, Albarracin C, Mills G . Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene. 2012; 31(40):4372-83. PMC: 3326223. DOI: 10.1038/onc.2011.608. View

4.
Aubele M, Auer G, Walch A, Munro A, Atkinson M, Braselmann H . PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer. 2007; 96(5):801-7. PMC: 2360069. DOI: 10.1038/sj.bjc.6603613. View

5.
Llor X, Serfas M, Bie W, Vasioukhin V, Polonskaia M, Derry J . BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res. 1999; 5(7):1767-77. View